Moreover, we demonstrated that a combination of NNMT inhibitor and EGFR-TKI strikingly suppressed EGFR-TKI-resistant NSCLC cell growth both in vitro and in vivo, which might be a promising strategy for the treatment of NSCLC patients with acquired resistance to EGFR-TKI. The gene discussed is NNMT; the disease is non-small cell lung carcinoma.